Shawn Cao

Shawn Cao


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
LYLinda Yi
Linda Yi
CCCyrille Chery
Cyrille Chery
FNFelix Nikels
Felix Nikels
FJFriederike Junge
Friederike Junge
VBVirginie Le Brun
Virginie Le Brun

21 August 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
LYLinda Yi
Linda Yi
CCCyrille Chery
Cyrille Chery
FNFelix Nikels
Felix Nikels
FJFriederike Junge
Friederike Junge
VBVirginie Le Brun
Virginie Le Brun

1 June 2009 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
SCShawn Cao
Shawn Cao
JPJoey Pollastrini
Joey Pollastrini
YJYijia Jiang
Yijia Jiang
Field flow fractionation (FFF) is a technique that holds great promise for the analysis and characterization of protein aggregates and particles, due to its wide dynamic range and matrix-free separation mechanism. FFF can be routinely used to achieve good monomer-oligomer separation and quantification for a variety of protein types, and is a reasonable choice for an orthogonal method for size exclusion chromatography and analytical ultracentrifugation. Quantifying sub-micrometer particles in protein therapeutics is a potential of the FFF technique that is yet to be realized, due to the lack of detection with sufficient sensitivity. In this article the effect of several important parameters on the optimization of FFF analyses are explored, and the strengths, weaknesses, and potential new applications of the technique are discussed.

1 January 2020 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
NJNancy Jiao
Nancy Jiao
GBGregory V. Barnett
Gregory V. Barnett
TCTwinkle R. Christian
Twinkle R. Christian
LNLinda O. Narhi
Linda O. Narhi
NJNathan H. Joh
Nathan H. Joh
SCShawn Cao
Shawn Cao

22 July 2021 in BioDrugs
Verified
Journal Article
Open access
PDF file
KHKatariina M. Hutterer
Katariina M. Hutterer
AIAnna Ip
Anna Ip
SKScott Kuhns
Scott Kuhns
SCShawn Cao
Shawn Cao
WMWikstroem Mats
Wikstroem Mats
JLJennifer Liu
Jennifer Liu
Background ABP 959 is one of the first proposed biosimilars to eculizumab reference product (RP), a recombinant IgG2/4Ƙ monoclonal antibody (mAb) that binds human C5 complement protein and inhibits C5 cleavage to C5a and C5b, preventing the generation of the terminal complement complex C5b-9. Eculizumab RP is approved for the treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, myasthenia gravis in patients who are anti-acetylcholine receptor antibody positive, and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. Objectives The objective of this work was to comparatively assess analytical (structural and functional) similarity between ABP 959 and eculizumab RP using sensitive, state-of-the art analytical methods capable of detecting minor differences in product quality attributes. Methods Comprehensive analytical (structural and functional) characterization utilizing orthogonal techniques was performed using multiple lots of ABP 959 and eculizumab RP over several years applying > 40 state-of-the-art assays. Comparisons were performed to investigate the primary structure and post-translational modifications including glycans, higher-order structure, particles and aggregates, product-related structures and impurities, thermal stability and forced degradation, general properties, and biological properties mediated by target binding. Results Results confirmed that ABP 959 had the same amino acid sequence, similar primary structure, higher-order structure, post-translational profiles, and the same protein content and concentration (e.g., ABP 959: 9.4–10.0; eculizumab EU: 9.4–10.0; eculizumab US: 9.3–10.3 mg/mL) as well as biological activity as eculizumab RP. Conclusions Based on these results, it can be concluded that ABP 959 is analytically similar to eculizumab RP.

1 August 2016 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
DSDaniel Some
Daniel Some
JPJoseph Pollastrini
Joseph Pollastrini
SCShawn Cao
Shawn Cao